Bristol Myers Squibb Data Engineer Salary by Level

Of the 24 data engineering reports in the pool, a portion are fully verified offers with base, bonus, and equity confirmed; the rest are base-only public filings where total comp is modeled from ratios observed across peer pharma companies. The split matters because a base-only filing at a company like Bristol Myers Squibb, where bonus and equity are meaningful, will understate realized pay if you read the base figure as a proxy for total comp. Reports skew toward senior and staff levels, which is where BMS actually hires, so the upper rungs of this 3-level ladder carry more reports and deserve more weight than the entry figure. The most recent data reflects offers through Aug 2, 2026; pharma comp bands tend to move slowly, so vintage is less of a concern here than at a fast-moving tech employer, but any individual report more than 18 months old should be read as a floor, not a ceiling.

Bristol Myers Squibb comp follows a structure common in large pharma: a fixed base, an annual performance bonus expressed as a percentage of base, and an equity component delivered as RSUs vesting over several years. At the senior and staff levels, the bonus target is material enough that waiting until the payout date matters for realized annual income; engineers who leave mid-year typically forfeit the unpaid portion. RSU grants at BMS vest on a schedule tied to grant date rather than hire date, so an engineer joining mid-cycle will carry unvested equity from multiple grants simultaneously after the first refresh cycle. The $190K median at senior and $204K at L6 reflect total comp as reported, but the cash-in-hand in any given year depends on where you are in the vesting calendar. Bonus payouts are tied to both company performance and individual rating, so realized total comp can move meaningfully even when base bands stay fixed.

Bristol Myers Squibb data engineering pay sits in line with other Healthcare companies, which is a reasonable outcome given BMS's position in the sector. The likeliest read is that BMS targets market rate rather than a premium, consistent with a company that competes on mission, stability, and domain depth rather than comp. Pharma employers at this scale generally set bands using Radford or Willis Towers Watson benchmarks and adjust infrequently; the result is comp that tracks the sector median closely but rarely jumps ahead of it. A secondary factor is that BMS draws engineers who want regulated-data experience, clinical domain exposure, or a large-scale Databricks environment, and that candidate pool is willing to accept sector-standard pay in exchange for the specialization. Companies without those credentials pull engineering talent with comp premiums BMS does not need to match. The $106K entry point at L4 reflects that BMS hires experienced engineers, not entry-level graduates, so the floor is set by mid-career market rates.

The $190K to $204K gap between senior and staff is real, and targeting L6 before engaging is the single highest-value decision you can make if your experience supports it. BMS runs structured bands, so base is largely fixed once the level is set; arguing the band up after an offer is extended rarely moves the number. What does flex is the RSU grant size, which carries more discretion than base and is worth pressing on specifically, with a competing offer in hand, rather than negotiating total comp as a single figure. A competing offer from another pharma or life-sciences employer lands harder than one from a tech company, because BMS calibrates to other Healthcare companies and a tech offer reads as a different market to the recruiter. If you're at the senior-to-staff boundary on experience, push for the L6 classification before signing; reclassification after onboarding is slow and uncommon at a company with this band structure.